培美曲塞维持治疗晚期非小细胞肺癌临床疗效的Meta分析

doi:10.11904/j.issn.1002-3070.2016.01.006

实用肿瘤学杂志 ›› 2016, Vol. 30 ›› Issue (1): 28-35.doi: 10.11904/j.issn.1002-3070.2016.01.006

培美曲塞维持治疗晚期非小细胞肺癌临床疗效的Meta分析

成龙, 周建国, 周航

遵义医学院附属肿瘤科(遵义 563000)

收稿日期:2015-11-18 出版日期:2016-02-28 发布日期:2016-02-25
通讯作者: 周航,E-mail:zhouhang6618@sina.com
作者简介:成龙,男,(1986-),硕士研究生,从事肿瘤综合治疗的研究

Maintenance therapy with pemetrexed for advanced non-small cell lung cancer:A Meta-analysis of RCTs

CHENG Long, ZHOU Jianguo, ZHOU Hang

Department of Oncology,The Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China

Received:2015-11-18 Online:2016-02-28 Published:2016-02-25

摘要/Abstract

摘要： 目的本研究对培美曲塞维持治疗晚期非小细胞肺癌的临床疗效进行Meta分析。方法计算机检索Cochrane、Pubmed、Web of science、Embase、临床试验等数据库,同时追溯参考文献。收集培美曲塞维持治疗和最佳支持治疗(Best supportive care,BSC)对非小细胞肺癌相关指标进行随机对照试验(Randomized controlled trial,RCT),根据Cochrane系统评价手册5.3质量评价标准评价,采用Stata 12.0软件和Revman5.3进行Meta分析及GRADEpro软件进行证据的评级。结果共纳入3篇随机对照试验,共1257名研究对象,Meta分析结果显示,与BSC相比培美曲塞可以延长无进展生存期(Pogression free survival,PFS)(HR=0.55,95%CI:0.48~0.64),以及总生存期(Overall survival,OS)(HR=0.76,95%CI:0.65~0.88),但客观缓解率(Objective response rate,ORR)无统计学意义(RR=0.97,95%CI:0.86~1.10)。结论与BSC相比,培美曲塞组可明显延长非小细胞肺癌的无进展生存期、总生存期,但在客观缓解率上影响并不显著。

关键词: 培美曲塞, 非小细胞肺癌, 维持治疗, Meta分析

Abstract: Objective This paper aims to assess the clinical efficacy of pemetrexed maintenance therapy in patients with advanced non-small cell lung cancer(NSCLC)through Meta analysis.Methods Systematic literature searches were performed in Cochrane、Pubmed,Web of science,Embase and ClinicalTrials databases.The related references had been traced.We made quality assessment of qualified randomized controlled trials(RCTs)of pemetrexed maintenance therapy compared with best supportive care(BSC)in advanced NSCLC.Besides,we utilized stata 12.0,Revman 5.3 and GRADEpro software to evaluate the overall quality of the evidence,according to the Cochrane collaboration to perform Meta-analysis.Results Three RCTs were eligible and included 1257 patients.Meta-analysis Results suggested that:compared to BSC,pemetrexed maintenance therapy had a statistically significant benefit in improving progression-free survival(PFS)(HR = 0.55,95% CI:0.48~0.64)and overall survival(HR=0.76,95%CI:0.65~0.88).The Objective response(ORR)did not reach statistical significance(RR=0.97,95%CI:0.86~1.10).Conclusion Compared with BSC,pemetrexed maintenance therapy statistically significantly improve PFS and OS,but has no demonstrable impact on ORR in patients with advanced NSCLC.

Key words: Pemetrexed, Non-small cell lung cancer, Maintenance therapy, Meta-analysis

中图分类号:

R734.2

成龙, 周建国, 周航. 培美曲塞维持治疗晚期非小细胞肺癌临床疗效的Meta分析[J]. 实用肿瘤学杂志, 2016, 30(1): 28-35.

CHENG Long, ZHOU Jianguo, ZHOU Hang. Maintenance therapy with pemetrexed for advanced non-small cell lung cancer:A Meta-analysis of RCTs[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 28-35.

参考文献

1 Siegel R,Ma J,Zou Z,et al.Cancer statistics,2014[J].CA Cancer J Clin,2014,64(1):9-29.
2 Chen W,Zheng R,Zeng H,et al.Annual report on status of cancer in China[J],2011,Chin J Cancer Res,2015,27(1):2-12.
3 Pfister DG,Johnson DH,Azzoli CG,et al.American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline:Update 2003[J].J Clin Oncol,2004,22(2):330-353.
4 Izzedine H.Pemetrexed nephrotoxicity[J].Bull Cancer,2015,102(2):190-197.
5 周建国,周权,马虎.EpiData软件在定量系统评价数据提取中的应用[J].循证医学,2014,14(6):361-363.
6 Mubarak N,Gaafar R,Shehata S,et al.A randomized,phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced,non-squamous,non-small cell lung cancer[J].BMC Cancer,2012,12(423):1407-2407.
7 Ciuleanu T,Brodowicz T,Zielinski C,et al.Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer:a randomised,double-blind,phase 3 study[J].Lancet,2009,374(9699):1432-1440.
8 Paz-Ares L,de Marinis F,Dediu M,et al.Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer(PARAMOUNT):a double-blind,phase 3,randomised controlled trial[J].The Lancet Oncology,2012,13(3):247-255.
9 Paz-Ares LG,de Marinis F,Dediu M,et al.PARAMOUNT:Final overall survival results of the phase Ⅲ study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer[J].J Clin Oncol,2014,31(23):2895-2902.
10 Genova C,Rijavec E,Truini A,et al,Pemetrexed for the treatment of non-small cell lung cancer[J].Expert Opin Pharmacother,2013,14(11):1545-1558.
11 Baldwin CM,Perry CM.Pemetrexed:a review of its use in the management of advanced non-squamous non-small cell lung cancer[J].Drugs,2009,69(16):2279-2302.
12 Belani CP,Wu YL,Chen YM,et al.Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from east Asia with advanced,nonsquamous non-small cell lung cancer[J].Journal of Thoracic Oncology,2012,7(3):567-573.
13 Shi Y,Sun Y.Medical management of lung cancer:Experience in China[J].Thorac Cancer,2015,6(1):10-16.
14 Balshem H,Helfanda M,Schunemann HJ,et al.GRADE指南证据质量分级[J].中国循证医学杂志,2011,11(4):451-455.

[1]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[2]	方琳, 刘超, 张纯慧, 张艳桥. 转移性结直肠癌维持治疗的研究现状与治疗策略[J]. 实用肿瘤学杂志, 2019, 33(2): 173-178.
[3]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[4]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[5]	蔡静, 候玥. 非小细胞肺癌患者血清miR-195的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 415-419.
[6]	崔晓燕, 涂青, 甘建辉. 纳布啡与羟考酮自控镇痛对非小细胞肺癌患者术后免疫因子水平影响的比较[J]. 实用肿瘤学杂志, 2018, 32(4): 309-314.
[7]	雷俊华, 许冠华, 曾江正, 黄芬, 何志惠, 卢彦达. 隐丹参酮联合顺铂抗非小细胞肺癌NCI-H1975细胞JAK2/STAT3机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 198-202.
[8]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[9]	杜夜生, 胡松柳, 徐向英. 非小细胞肺癌寡转移的立体定向放射治疗研究[J]. 实用肿瘤学杂志, 2018, 32(2): 154-158.
[10]	孙明亮, 徐建宇, 徐向英. 早期非小细胞肺癌立体定向放疗的相关研究[J]. 实用肿瘤学杂志, 2018, 32(1): 53-56.
[11]	代欣综述, 张大昕审校. 非小细胞肺癌抗血管生成治疗研究现状[J]. 实用肿瘤学杂志, 2017, 31(5): 472-476.
[12]	胡海峰, 冯谢敏, 乔健, 段伟, 刘宁宁, 孙晓东. miR-345在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2017, 31(2): 117-122.
[13]	张锐，王智煜，王帅，赵晖. 重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 527-522.
[14]	崔君鹏, 刘宝林. VDR基因FokI位点多态性与结直肠癌易感性之间关系的Meta分析[J]. 实用肿瘤学杂志, 2016, 30(5): 400-408.
[15]	任凤海,王丹丹,王俊峰,徐海,徐世东. 单孔与单操作孔电视辅助胸腔镜手术治疗ⅠA期非小细胞肺癌的临床对比研究[J]. 实用肿瘤学杂志, 2016, 30(4): 327-331.

培美曲塞维持治疗晚期非小细胞肺癌临床疗效的Meta分析

Maintenance therapy with pemetrexed for advanced non-small cell lung cancer:A Meta-analysis of RCTs

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价